Search

Your search keyword '"Edmund Huang"' showing total 92 results

Search Constraints

Start Over You searched for: Author "Edmund Huang" Remove constraint Author: "Edmund Huang" Language undetermined Remove constraint Language: undetermined
92 results on '"Edmund Huang"'

Search Results

1. A Banff-based histologic chronicity index is associated with graft loss in patients with a kidney transplant and antibody-mediated rejection

2. Diagnostic Potential of Minimally Invasive Biomarkers: A Biopsy-centered Viewpoint From the Banff Minimally Invasive Diagnostics Working Group

3. Importance of IL-6 inhibition in prevention and treatment of antibody-mediated rejection in kidney allografts

4. Evaluation of Clazakizumab (Anti–Interleukin-6) in Patients With Treatment-Resistant Chronic Active Antibody-Mediated Rejection of Kidney Allografts

5. Imlifidase for the treatment of anti-HLA antibody-mediated processes in kidney transplantation

6. The Banff 2022 Kidney Meeting Report: Re-Appraisal of Microvascular Inflammation and the Role of Biopsy-Based Transcript Diagnostics

7. The Banff 2022 Kidney Meeting Work Plan: Data-Driven Refinement of the Banff Classification for Renal Allografts

8. Diagnostic Potential of Minimally Invasive Biomarkers: A Biopsy-centered Viewpoint From the Banff Minimally Invasive Diagnostics Working Group

9. An Assessment of the Value of Donor-derived Cell-free DNA Surveillance in Patients With Preserved Kidney Allograft Function: Erratum

10. Rationalizing Incompatible Living Donor Kidney Transplantation for Highly Sensitized Candidates

12. Imlifidase as a Potential Treatment for Antibody-Mediated Rejection

14. Compassionate Use of Tocilizumab for Treatment of SARS-CoV-2 Pneumonia

15. Human Leukocyte Antigen Homozygosity Contributes to Sensitization in Kidney Transplant Candidates

16. Assessment of humoral and cellular immune responses to SARS CoV-2 vaccination (BNT162b2) in immunocompromised renal allograft recipients

19. Clazakizumab for desensitization in highly sensitized patients awaiting transplantation

20. Donor-derived cell-free DNA in kidney transplantation: evolving concepts and potential limitations

21. Use of Rituximab for persistent EBV DNAemia, and Its effect on donor‐specific antibody development in pediatric renal transplant recipients: A case series

22. Development of CMV-specific cytotoxic T cells (CMV-Tc) in pediatric renal transplant recipients with CMV viremia

23. Three-Year Outcomes of a Randomized, Double-Blind, Placebo-Controlled Study Assessing Safety and Efficacy of C1 Esterase Inhibitor for Prevention of Delayed Graft Function in Deceased Donor Kidney Transplant Recipients

24. Early clinical experience using donor-derived cell-free DNA to detect rejection in kidney transplant recipients

26. Infectious Complications in Tocilizumab-treated Kidney Transplant Recipients

27. Chronic active T cell-mediated rejection is variably responsive to immunosuppressive therapy

28. HLA Homozygosity and Likelihood of Sensitization in Kidney Transplant Candidates

29. Tocilizumab for Covid-19 - The Ongoing Search for Effective Therapies

30. Dynamic prediction of renal survival using artificial intelligence: an international study of deeply phenotyped cohorts of kidney transplant recipients

31. COVID-19: Review of a 21st Century Pandemic from Etiology to Neuro-psychiatric Implications

32. Donor-derived Cell-free DNA Combined With Histology Improves Prediction of Estimated Glomerular Filtration Rate Over Time in Kidney Transplant Recipients Compared With Histology Alone

33. Interleukin-6: An Important Mediator of Allograft Injury

34. The role of novel therapeutic approaches for prevention of allosensitization and antibody-mediated rejection

35. Interleukin 6: Pathogenic Potential and Therapeutic Approaches in Autoimmunity and Transplant Rejection

36. Combined Dual‐Kidney Liver Transplantation in the United States: A Review of United Network for Organ Sharing/Organ Procurement and Transplantation Network Data Between 2002 and 2012

37. Increased Frequency of BK Virus-Specific Polyfunctional CD8+ T Cells Predict Successful Control of BK Viremia After Kidney Transplantation

38. Acute Kidney Allograft Rejection Precipitated by Lenalidomide Treatment for Multiple Myeloma

39. Linguistic Isolation and Access to the Active Kidney Transplant Waiting List in the United States

40. TCT CONNECT-383 Impact of Coronary Lesion Severity on Long-Term Cardiac Outcomes in Renal Transplant Candidates

41. CLAZAKIZUMAB (ANTI-IL-6 MONOCLONAL) TREATMENT OF PATIENTS WITH CHRONIC & ACTIVE ANTIBODY-MEDIATED REJECTION POST-KIDNEY TRANSPLANTATION (NCT03380377)

42. CLAZAKIZUMAB® (ANTI-IL-6) FOR DESENSITIZATION OF HIGHLY-HLA SENSITIZED PATIENTS AWAITING KIDNEY TRANSPLANT (NCT03380962)

44. Immunoglobulin G–Degrading Enzyme of Streptococcus pyogenes (IdeS), Desensitization, and the Kidney Allocation System

45. JC virus-associated nephropathy in a post-heart and -kidney transplantation patient

46. Outcomes of Conversion From Calcineurin Inhibitor to Belatacept-based Immunosuppression in HLA-sensitized Kidney Transplant Recipients

47. Impact of Tocilizumab (Anti-IL-6R) Treatment on Immunoglobulins and Anti-HLA Antibodies in Kidney Transplant Patients With Chronic Antibody-mediated Rejection

48. Clinical Relevance of Posttransplant DSAs in Patients Receiving Desensitization for HLA-incompatible Kidney Transplantation

49. CLAZAKIZUMAB (ANTI-IL-6) INDUCES FOXP3+ TREGS IN HIGHLY HLA SENSITIZED PATIENTS RECEIVING HLAI KIDNEY TRANSPLANTATION (NCT03380962)

50. IMPACT OF PERCUTANEOUS CORONARY INTERVENTION IN RENAL TRANSPLANT CANDIDATES ON LONG TERM CARDIAC OUTCOMES

Catalog

Books, media, physical & digital resources